• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

BioDelivery Sciences beats Q2 rev estimates, misses on EPS

August 10, 2017 By Sarah Faulkner

BioDelivery SciencesShares in BioDelivery Sciences International (NSDQ:BDSI) fell today after the pharmaceutical company beat sales estimates but missed earnings expectations on Wall Street with its second quarter results.

The Raleigh, N.C.-based company posted a net loss of -$14.9 million on sales of $8.7 million for the 3 months ended June 30, paring losses by 9.7% on sales growth of 75% compared with the same period last year.

Adjusted to exclude 1-time items, earnings per share were -27¢, behind earnings estimates on The Street. Analysts were looking for sales of $8.5 million.

“The U.S. currently faces a very serious crisis with regard to prescription opioid abuse, addiction and overdose.  Our two buprenorphine-containing products provide important options to address the needs of those with chronic pain and opioid dependence, and we believe this is becoming increasingly recognized by healthcare providers, and that these dynamics are likely aiding our commercial performance with Belbuca,” president & CEO Mark Sirgo said in prepared remarks.  “Our strong start with our focused commercial effort behind Belbuca continued in the second quarter, with solid 44% growth in Belbuca net sales to $6.6 million compared to net sales of $4.6 million in the first quarter.  This is accentuated by sales from May onward that exceeded the previous sales peak reached by our former commercial partner Endo in December 2016. The increasing number of both prescriptions and number of Belbuca prescribers provide us with the confidence that our commercial strategy is working, and we anticipate continued growth. We also believe that the addition of government payers, such as Medicare Part D, which represents nearly 40% of the total prescriptions for long-acting opioids, provides further opportunity for growth as we look ahead to 2018.”

“We also achieved important progress with our Belbuca licensing efforts outside the U.S.  Our second quarter marketing approval for Belbuca by Health Canada was followed shortly thereafter by our licensing agreement with Purdue (Canada) for the licensing, distribution, marketing, and sale of Belbuca in Canada.  We anticipate the launch will take place early next year.  Beyond this agreement, we are focused on advancing toward additional commercial transactions for ex-U.S. rights to Belbuca this year, which will further support sustained future growth and our expansion strategy for this important product,” Sirgo added.

“Our cash on hand, in combination with expected Belbuca and Bunavail revenue, provide us the capital runway to support our current operating plan into the second half of 2018.  In addition, this runway does not include our ability to access up to an additional $30 million from our current CRG loan, the availability of which is dependent upon BDSI achieving certain funding conditions.”

BDSI shares were trading at $2.92 apiece today in morning activity, down -7.1%.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Drug-Device Combinations, Featured, MassDevice Earnings Roundup, Pain Management, Pharmaceuticals, Sublingual films, Wall Street Beat Tagged With: BioDelivery Sciences International

IN CASE YOU MISSED IT

  • Medtronic enrolls first patient in study for Onyx liquid embolic system
  • BD issues voluntary recall on certain Alaris infusion pump modules
  • Sequel Med Tech expects full twiist launch in the fall
  • Insulet hires new chief HR officer from J&J
  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS